Procter & Gamble Health (BOM:500126) Other Current Receivables: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500126 Procter & Gamble Health Ltd BOM:500126
76 GF Score
Price ₹5,731.30
GF Value ₹5,846.08
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Procter & Gamble Health Other Current Receivables?

Procter & Gamble Health BOM:500126 -0.60% 76 Other Current Receivables is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:500126 with a GF Score™ of 76/100 and a GF Value™ of ₹5,846.08 (Fairly Valued). The stock has 2 warning signs investors should review.

Procter & Gamble Health's Other Current Receivables for the quarter that ended in Jun. 2026 was ₹0 Mil.

Procter & Gamble Health's annual Other Current Receivables increased from Jun. 2023 (₹140.90 Mil) to Jun. 2024 (₹150.90 Mil) and increased from Jun. 2024 (₹150.90 Mil) to Mar. 2026 (₹182.60 Mil).

Procter & Gamble Health Other Current Receivables Related Terms

Procter & Gamble Health Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Procter & Gamble Health's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Procter & Gamble Health Other Current Receivables Chart

Procter & Gamble Health Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Jun21 Jun22 Jun23 Jun24 Mar26
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.50 90.30 140.90 150.90 182.60

Procter & Gamble Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 16.90 0.00 182.60 0.00
BOM:500126
76GF Score
Procter & Gamble Health Ltd BOM:500126
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Procter & Gamble Health Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of ₹0 Mil mean?
Procter & Gamble Health (BOM:500126) has a Other Current Receivables of ₹0 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Procter & Gamble Health and its competitors.
Is Procter & Gamble Health's Other Current Receivables too high?
Procter & Gamble Health's current Other Current Receivables is ₹0 Mil. Overall, Procter & Gamble Health has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's Other Current Receivables compare to ZTS?
Procter & Gamble Health's Other Current Receivables of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Procter & Gamble Health and its competitors. Procter & Gamble Health's current Other Current Receivables is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Fairly Valued. The stock's GF Value™ is ₹5,846.08, compared to a current price of ₹5,731.30 — trading 2% below its estimated fair value. The current Other Current Receivables is ₹0 Mil. Procter & Gamble Health's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current Other Current Receivables is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?

Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be undervalued. The current stock price of ₹5,731.30 is trading 2% below its estimated GF Value™ of ₹5,846.08. GuruFocus considers Procter & Gamble Health to be Fairly Valued.

Key valuation signals for BOM:500126:

  • Other Current Receivables: ₹0 Mil
  • GF Value™: ₹5,846.08 vs. price of ₹5,731.30 (2% below fair value)
  • GF Score™: 76/100 with 2 warning signs

No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Procter & Gamble Health Business Description

Other Exchanges PGHL:India
Address Cardinal Gracias Road, Ground Floor And First Floor, P&G Plaza, Chakala, Andheri East, Mumbai, MH, IND, 400099
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
76GF Score

Get the complete analysis for BOM:500126

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5,731.30
Price
₹5,846.08
GF Value